What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis?

Kornelis S. M. van der  Geest; Maria Sandovici; Yannick van Sleen; Jan-Stephan Sanders; Nicolaas A. Bos; Wayel H. Abdulahad; Coen A. Stegeman; Peter Heeringa; Abraham Rutgers; Cees G. M. Kallenberg; Annemieke M. H. Boots; Elisabeth Brouwer

doi:10.1002/art.40520

What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis?

Kornelis S. M. van der Geest, Maria Sandovici, Yannick van Sleen, Jan-Stephan Sanders, Nicolaas A. Bos, Wayel H. Abdulahad, Coen A. Stegeman, Peter Heeringa, Abraham Rutgers, Cees G. M. Kallenberg, Annemieke M. H. Boots, Elisabeth Brouwer^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

53 Citations (Scopus)

539 Downloads (Pure)

Abstract

Giant cell arteritis (GCA) is an autoimmune vasculitis affecting large and medium-sized arteries. Ample evidence indicates that GCA is a heterogeneous disease in terms of symptoms, immune pathology, and response to treatment. In the current review, we discuss the evidence for disease subsets in GCA. We describe clinical and immunologic characteristics that may impact the risk of cranial ischemic symptoms, relapse rates, and long-term glucocorticoid requirements in patients with GCA. In addition, we discuss both proven and putative immunologic targets for therapy in patients with GCA who have an unfavorable prognosis. Finally, we provide recommendations for further research on disease subsets in GCA.

Original language	English
Pages (from-to)	1366-1376
Number of pages	11
Journal	Arthritis & Rheumatology
Volume	70
Issue number	9
DOIs	https://doi.org/10.1002/art.40520
Publication status	Published - Sept-2018

Keywords

PLACEBO-CONTROLLED TRIAL
POPULATION-BASED COHORT
VARICELLA-ZOSTER-VIRUS
ERYTHROCYTE SEDIMENTATION-RATE
UNINFLAMED TEMPORAL ARTERY
ENDOTHELIAL GROWTH-FACTOR
LARGE-VESSEL VASCULITIS
PERMANENT VISUAL-LOSS
POLYMYALGIA-RHEUMATICA
ISCHEMIC COMPLICATIONS

Access to Document

10.1002/art.40520Licence: CC BY-NC

What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis?Final publisher's version, 285 KBLicence: CC BY-NC

Handle.net

Persistent link

Cite this

@article{6efb9497336a4784977cb27dd4341f82,

title = "What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis?",

abstract = "Giant cell arteritis (GCA) is an autoimmune vasculitis affecting large and medium-sized arteries. Ample evidence indicates that GCA is a heterogeneous disease in terms of symptoms, immune pathology, and response to treatment. In the current review, we discuss the evidence for disease subsets in GCA. We describe clinical and immunologic characteristics that may impact the risk of cranial ischemic symptoms, relapse rates, and long-term glucocorticoid requirements in patients with GCA. In addition, we discuss both proven and putative immunologic targets for therapy in patients with GCA who have an unfavorable prognosis. Finally, we provide recommendations for further research on disease subsets in GCA.",

keywords = "PLACEBO-CONTROLLED TRIAL, POPULATION-BASED COHORT, VARICELLA-ZOSTER-VIRUS, ERYTHROCYTE SEDIMENTATION-RATE, UNINFLAMED TEMPORAL ARTERY, ENDOTHELIAL GROWTH-FACTOR, LARGE-VESSEL VASCULITIS, PERMANENT VISUAL-LOSS, POLYMYALGIA-RHEUMATICA, ISCHEMIC COMPLICATIONS",

author = "{van der Geest}, {Kornelis S. M.} and Maria Sandovici and {van Sleen}, Yannick and Jan-Stephan Sanders and Bos, {Nicolaas A.} and Abdulahad, {Wayel H.} and Stegeman, {Coen A.} and Peter Heeringa and Abraham Rutgers and Kallenberg, {Cees G. M.} and Boots, {Annemieke M. H.} and Elisabeth Brouwer",

year = "2018",

month = sep,

doi = "10.1002/art.40520",

language = "English",

volume = "70",

pages = "1366--1376",

journal = "Arthritis & Rheumatology",

issn = "2326-5191",